Authors' Names

Jill FarnsworthFollow

Presentation Type

Oral Presentation

Area of Focus

Life Sciences

Abstract

Amino acids are pivotal to our health and it’s no surprise that dysregulation of these essential biomolecules are associated with various disorders. We propose that manipulation of a certain amino acid, D-serine, has potential to treat learning and memory disorders like Alzheimer’s Disease (AD) and schizophrenia. These disorders are associated with aberrant activation of N-methyl-D-aspartate receptors (NMDARs) and D-serine is important in their regulation. In order to further investigate the potential of D-serine as a therapeutic target, we have developed and patented (US patent 20130065935) a compound that acts to regulate levels of D-serine. This compound could prove to be a novel therapeutic target to treat neuropsychological disorders.

Share

COinS
 
Apr 14th, 9:40 AM Apr 14th, 10:00 AM

ASCTs could prove to be a useful therapeutic target for neuropsychological disorders

Amino acids are pivotal to our health and it’s no surprise that dysregulation of these essential biomolecules are associated with various disorders. We propose that manipulation of a certain amino acid, D-serine, has potential to treat learning and memory disorders like Alzheimer’s Disease (AD) and schizophrenia. These disorders are associated with aberrant activation of N-methyl-D-aspartate receptors (NMDARs) and D-serine is important in their regulation. In order to further investigate the potential of D-serine as a therapeutic target, we have developed and patented (US patent 20130065935) a compound that acts to regulate levels of D-serine. This compound could prove to be a novel therapeutic target to treat neuropsychological disorders.